A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism

Trial Profile

A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2015

At a glance

  • Drugs Enclomifene (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions; Registrational
  • Acronyms DEXA
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 02 Feb 2015 Data from this trial supported an NDA submission to the US FDA for enclomifene in the treatment of secondary hypogonadism in overweight men, according to a Repros Therapeutics media release.
    • 21 Oct 2014 An NDA for enclomifene is expected to be filed to the US FDA around the end of 2014, according to a Repros Therapeutics media release.
    • 21 Oct 2014 Results published in a Repros Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top